Biotech

Administrator pinned this post

1 month ago

Get $10 for Every 100 Followers!

Don't miss out on this limited-time offer! For every 100 followers you gain, you'll receive $10.

Hurry, the campaign ends without prior notice! Be sure to take advantage before it’s too late.

For more details, check the banner.

science

17 days ago

PARIS, Dec 4 (Reuters) - The European Union has reached a preliminary deal on how to regulate gene-edited crops in a move that could ease the development of new varieties in a region long ‌wary of biotech innovations in food.
The EU has debated for years how to regulate so-called new ‌genomic techniques (NGT), which can edit the genetic material of an organism without introducing traits from another species.
Proponents say the technology accelerates naturally-occurring mutations and offers a response to climate and environmental pressures, while critics bracket it with genetically modified o

science

26 days ago

In the fast-moving world of biotech innovation, few figures have commanded attention in 2025 the way Ben Lamm has.
As founder and CEO of Colossal Biosciences, he has transformed what sounded like science fiction into a high-stakes, headline-dominating movement.
His company’s mission, once dismissed as sensational, now sits at the center of global discussions about climate solutions, genetics, and the future of life itself.
Ben Lamm’s rise began with a concept that seemed almost too audacious to be real: bringing extinct species back into the modern world.
Colossal Biosciences quickly earne

science

27 days ago

By Karen Roman
Imviva Biotech said it will present its progress in allogenic cell therapy candidates in two oral presentations and five poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting, to be held on December 6-9, 2025, in Orlando, Florida.
The presentation will feature the company’s CAR-T cell therapy for multiple hematological conditions including severe aplastic anemia and acute lymphoblastic leukemia, called CTD402 and CTA311, the company stated.
“We will share the breadth and depth of our ANSWER platform, which addresses many limitations encountered

MatthewAnderson52

5 months ago

When a next-gen immunotherapy biotech needed a lab informatics solution that could scale with their science, they turned to Sapio.

With no-code flexibility and built-in sample management, Sapio helped ImmuneBridge move beyond the limits of its legacy ELN.

AnthonyDavis45

5 months ago

News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: https://ow.ly/KKEz50TTwo6.

Unlock expert ****** ysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.

News

7 months ago

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing cancer cells http://dlvr.it/TL7J51

http://dlvr.it/TL7J51

News

7 months ago

Positive trial results halting early? A win for patients if this oral antibiotic can replace IV treatments. Medical advancements like this are why we follow biotech news!